MENLO PARK, CA / ACCESS Newswire / October 20, 2026 / Edison Oncology Holding Corp. ("Edison Oncology" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies by unlocking the potential of existing drugs and compounds for genetically defined cancers, today announced the appointment of Michael Faber to its Board of Directors. The Company also announced that five abstracts have been accepted for presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026) in Philadelphia and the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona.

Mr. Faber has more than 25 years of experience investing in, operating and advising public and private companies. He is President and Chief Investment Officer of NextPoint Management Company, a family office he has led since 1996, and has led investments in more than 180 companies. He has served as chief executive officer of eight companies and on the boards of more than 40 public and private companies. He currently serves on the boards of CPI Aerostructures, Inc. (NYSE American: CVU) and Disciplined Growth Acquisition Corp. (Nasdaq: DGAC). Earlier in his career, he practiced law at Arnold & Porter. He is an honors graduate of the University of Chicago Law School, where he was a John M. Olin Fellow.

"Michael brings deep experience in capital formation, governance and public company oversight," said Jeffrey Bacha, Chief Executive Officer of Edison Oncology. "His addition strengthens our Board as we advance multiple clinical-stage programs that will be featured at peer-reviewed meetings this November."

"I believe the Company's approach of advancing drugs with established human safety data into biomarker-defined patient populations is a capital-efficient model for drug development," said Mr. Faber. "I look forward to working with the Board and management team."

Scientific Conference Presentation Highlights

EO3001 and EO4426 reflect the Edison Company's model: finding therapies with established human safety data and evidence of activity from prior third-party clinical trials, understanding through precision biology which patients are most likely to benefit, and advancing them in focused, biomarker-driven clinical studies. EO1001 is a new chemical entity that recently completed enrollment in its Phase 1-2a study.

EO3001 (elesclomol) is the Company's lead program with clinical experience involving more than 1,000 patients in prior third-party clinical trials. The Company's poster will present the scientific rationale and design of a planned Phase I/II study in solid tumors, with a focus on ARID1A-mutant cancers, which represent approximately 10% of solid tumors.

EO4426 (tezacitabine) is an oral, brain-penetrant agent studied in more than 400 patients in prior third-party clinical trials. The poster will present data supporting biomarker-directed development in central nervous system and other cancers.

EO1001 is an oral, brain-penetrant pan-ErbB inhibitor. Two SNO posters will focus on central nervous system cancers will report updated clinical results in advanced solid tumors, including recurrent glioblastoma patients whose tumors carry EGFR extracellular domain (ECD) alterations as well as laboratory findings showing EO1001 activity in patient-derived glioblastoma models with ECD alterations. At ENA, a separate poster will report safety, pharmacokinetics and preliminary clinical activity across diverse ErbB-driven tumors, including those harboring EGFR ECD alterations.

Presentation Details

SNO 2026 - Philadelphia, November 12-15, 2026. Poster session: Friday, November 13, 7:30-9:30 p.m. ET

• "Updated Phase 1-2a Results of EO1001, an Oral Brain-Penetrating Pan-ErbB Inhibitor, in Advanced Solid Tumors and Recurrent Glioblastoma with EGFR Extracellular Domain Alterations" (Abstract CTNI-45)
• "EO1001 Demonstrates Differentiated Activity in EGFR Extracellular Domain Mutant Glioblastoma Models Supporting Biomarker-Directed Clinical Development" (Abstract BIOM-74)
• "EO4426 Demonstrates Activity in Replication Stress and APOBEC-Enriched Tumor Models Supporting Biomarker-Directed Development in CNS Malignancies" (Abstract DNAR-18)

ENA 2026 - Barcelona, November 18-20, 2026. Poster display: Thursday, November 19, Exhibition Hall, Molecular Targeted Agents

• "Phase 1-2a Dose Escalation and Expansion of EO1001, an Oral Brain-Penetrant Pan-ErbB Inhibitor, in Advanced ErbB-Driven Solid Tumors: Safety, Pharmacokinetics, and Preliminary Clinical Activity Following Completion of Enrollment"
• "EO3001 (elesclomol), a Copper Ionophore that Exploits Ferredoxin-1 (FDX1) to Drive Cuproptosis in ARID1A-Mutant Solid Tumors: Preclinical Rationale and Design of an All-Comer Phase 1-2a Dose-Escalation Study with Prospective ARID1A Biomarker Stratification"

Posters will be available on the Company's website following each presentation.

About Edison Oncology

Edison Oncology is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined cancers with significant unmet need. The Company's applies advances in genomics, biomarker science and mechanistic biology to identify patient populations most likely to benefit from compounds with established clinical safety profiles and evidence of anticancer activity. Its capital-efficient development strategy combines internal development with strategic co-development and licensing partnerships while retaining meaningful development and commercial rights. To learn more, please visit https://www.edisononcology.com/ and follow us for updates on LinkedIn.

Contact

Hayden IR
Brett Maas
(646) 536-7331
brett@haydenir.com
or
James Carbonara
(646)-755-7412
james@haydenir.com

SOURCE: Edison Oncology